Trials / Completed
CompletedNCT05643885
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
Cost Comparison Between Apixaban and Low Molecular Weight Heparin (LMWH) Among Venous Thromboembolism (VTE) Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,304 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Conditions
Timeline
- Start date
- 2022-08-31
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2022-12-09
- Last updated
- 2025-10-20
- Results posted
- 2025-10-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05643885. Inclusion in this directory is not an endorsement.